Intrauterine growth restriction is a leading cause of perinatal morbidity and mortality (1) . Low birth weight is also associated with higher risk of cardiovascular disease in adulthood (2) . Placental function is essential for fetal growth, and placental vascular insufficiency, causing fetoplacental hypoxia, is an important cause of intrauterine growth restriction (3, 4) . Different angiogenic factors are expressed in the placenta, and circulating levels of angiogenic factors in the maternal circulation may be markers of placental function. Specifically, placental growth factor (PlGF), soluble fms-like tyrosine kinase 1 (Flt-1), and soluble endoglin may express angiogenic activity that is closely related to fetal growth restriction (5) (6) (7) (8) (9) (10) (11) (12) .
Different demands during pregnancy suggest that angiogenic factor levels at different stages of pregnancy could reflect different biologic processes. Thus, low concentrations of angiogenic factors in early pregnancy may indicate impaired placental development, whereas a strong subsequent increase in soluble Flt-1 and soluble endoglin may represent a response to the fetoplacental hypoxia that is associated with placental impairment (7, 11, 13, 14) . Previous studies suggest that low PlGF (8, 9, (15) (16) (17) (18) (19) (20) (21) (22) and high soluble endoglin levels (5, 6, 9, 12) throughout pregnancy are associated with fetal growth restriction. There is also evidence to suggest that low soluble Flt-1 in early pregnancy (10) and high soluble Flt-1 in late pregnancy (7, 12, 15, 16, (21) (22) (23) ) may be associated with fetal growth restriction.
Studies of angiogenic factors and fetal growth restriction require longitudinal blood sampling in a large number of pregnancies. Therefore, we conducted a nested case-control study among more than 26,000 pregnant women, from whom blood was collected in the first and second trimesters, and assessed levels of soluble Flt-1, PlGF, and soluble endoglin in relation to the risk of severe fetal growth restriction.
MATERIALS AND METHODS
Between June 1992 and May 1994, 35,940 women in Norway participated in a prospective study of Toxoplasma gondii infection in pregnancy (24) . All pregnant women who attended antenatal care in 11 of 19 counties in Norway were included in the study. A blood sample was drawn from each woman at about 10 weeks of gestation and, in women without antibodies to T. gondii, additional blood samples were drawn at about 23 weeks of gestation. Subsequent to the original study, we attempted to contact all participating women by mail in order to obtain their consent to use the data and blood samples for additional scientific purposes, and 29,072 women consented. Previously, case-control studies of fetal deaths and preeclampsia used blood samples from this cohort (25, 26) and, for this study, serum samples were available from 26,744 women.
We obtained information on pregnancy outcomes from the Medical Birth Registry of Norway (www.uib.no/mfr), where information on all births after 16 weeks of pregnancy is recorded. Information on each pregnancy and delivery is obtained by compulsory notification on standardized forms by midwives or obstetricians. We used small for gestational age (SGA) as an indicator of intrauterine growth restriction. We adjusted the birth weight for length of gestation and sex of offspring using norms from the Medical Birth Registry of Norway (27) , and we defined SGA as singleton infants with adjusted birth weight lower than the 2.5th percentile within our cohort. Thus, we randomly selected 250 women with SGA offspring and oversampled infants smaller than the lowest percentile of birth weight (n ¼ 150). To obtain controls, we randomly selected 390 women with singleton infants above the 2.5th percentile of birth weight. Women who developed preeclampsia (22 women in SGA pregnancies and 7 women in control pregnancies), experienced fetal death (1 woman in SGA pregnancy), and delivered infants with serious malformations (10 women in SGA and 5 women in control pregnancies) were excluded, leaving 217 SGA and 378 control pregnancies eligible for the study. Descriptive characteristics of SGA and control pregnancies are shown in Table 1 .
The study was approved by the Norwegian Data Inspectorate, the Regional Committee for Medical Research Ethics, and the Internal Review Board of the Medical Birth Registry of Norway.
Placental growth factor, soluble fms-like tyrosine kinase 1, and soluble endoglin
The first serum sample was collected around pregnancy week 10 (median, 10 weeks for both SGA and controls; range, 4-18 weeks), and the second sample was collected around week 23 (median, 23 weeks for both SGA and controls; range, 19-34 weeks), approximately coinciding with the first and second trimesters. Among a total of 595 women (217 with SGA infants and 378 controls), PlGF could be measured in samples from the first sampling period in 540 women, soluble Flt-1 in 559 women, and soluble endoglin in 486 women. In the second sampling period, PlGF was measured in 467 women, soluble Flt-1 in 469 women, and soluble endoglin in 422 women. The number of measurements for each gestational week of serum sampling is shown in Appendix Table 1 .
The sera were treated according to uniform standards and stored in 1 place at -20°C until analyzed. Concentrations of PlGF, soluble Flt-1, and soluble endoglin were determined by enzyme-linked immunosorbent assays from R&D Systems, Minneapolis, Minnesota. According to R&D Systems, minimal detectable levels were <7 pg/mL for PlGF, 3.5 pg/ Abbreviations: SGA, small for gestational age (neonates with adjusted birth weight lower than the 2.5th percentile, adjusted for length of gestation and infant's sex); SD, standard deviation. Figure 1 . Geometric mean levels of placental growth factor (PlGF) by week of gestation, in small-for-gestational-age (SGA) and control pregnancies, adjusted for maternal age and parity, in a case-control study among pregnancies in Norway between 1992 and 1994. mL for soluble Flt-1, and 0.007 ng/mL for soluble endoglin. Quantification ranges were 15.6-1,000 pg/mL for PlGF, 31.2-2,000 pg/mL for soluble Flt-1, and 0.156-10 ng/mL for soluble endoglin. The technicians performing the tests were blinded to the clinical outcome.
Statistical analysis
We used a multilevel mixed-effects linear regression model to calculate geometric mean serum concentrations of each angiogenic factor for each week of gestation and compared the respective levels in SGA and control pregnancies. The model included fractional polynomials that expressed log-transformed concentrations of the angiogenic factors by gestational age. The fractional polynomials were computed by using linear regression analysis and adjusted for maternal age and parity.
In the cross-sectional analyses for each blood sampling, we used logistic regression analysis to estimate odds ratios (with 95% confidence intervals) of SGA delivery according to percentile values of each angiogenic factor, as measured among controls (percentiles 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 95), using the 50th percentile as the reference. The model included restricted cubic splines for each angiogenic factor, and the analyses were conducted separately for the first and second sampling periods, with adjustment for gestational week of serum sampling, maternal age (<25, 25-29, 30-34, 35-39, or 40 years of age), and parity (0, 1, or 2 previous births).
Among women who had measurements in both sampling periods, we assessed the association of changes in angiogenic factor levels with risk of SGA delivery. On the basis of the distribution among controls, women were ranked by thirds, according to angiogenic factor concentrations in the first and second sampling periods. Using logistic regression analysis, we calculated odds ratios (with 95% confidence intervals) of SGA delivery according to changes in rank from the first to the second sampling. In the analyses, women who were ranked in the middle third in both sampling periods were used as the reference group. The results Figure 2 . Odds ratios of delivery of a small-for-gestational-age (SGA) infant, by levels of placental growth factor (PlGF) in the first (left) and second (right) sampling period, adjusted for maternal age, parity, and gestational week of sampling, in a case-control study among pregnancies in Norway between 1992 and 1994. The odds ratios are calculated at 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 95 percentiles of PlGF, by using the 50th percentile as the reference. CI, confidence interval; OR, odds ratio. were adjusted for gestational weeks at serum sampling, maternal age, and parity.
For each woman, we constructed a ratio of the concentrations of soluble Flt-1 and PlGF for each sampling period. This ratio was also divided into thirds on the basis of the distribution among controls. The purpose was to study whether the level of soluble Flt-1 relative to PlGF in the first and second sampling periods could be associated with SGA risk, because a high soluble Flt-1/PlGF ratio in the second trimester has previously been associated with preterm preeclampsia with SGA delivery (6) . In a final analysis, we studied the risks of SGA delivery of the soluble Flt-1/ PlGF ratio and soluble endoglin measured at the second sampling, by soluble Flt-1 level at the first sampling. STATA for Windows, version 10.0, software (StataCorp LP, College Station, Texas) was used for the statistical analyses.
RESULTS
Placental growth factor Figure 1 shows serum PlGF concentrations in control pregnancies and pregnancies with SGA delivery. In controls, there was a moderate increase in PlGF during the first trimester (from 10 to 35 pg/mL), followed by a strong increase to approximately 500 pg/mL at week 30 of gestation. In SGA pregnancies, PlGF levels followed a similar pattern, but the increase in PlGF leveled off at about 26 weeks of gestation.
The cross-sectional analysis showed that low levels of PlGF, in both the first and the second sampling periods, were associated with higher risk of SGA delivery (Figure 2) , with similar risk patterns in both sampling periods.
In the longitudinal analysis of changes in PlGF from the first to the second sampling period (Table 2) , women with low PlGF (lowest third) at both periods were at nearly 4 times higher risk (odds ratio (OR) ¼ 3.8, 95% confidence interval (CI): 1.6, 8.8) of SGA delivery, compared with women with PlGF in the middle third at both samplings.
Soluble fms-like tyrosine kinase 1
In control pregnancies, soluble Flt-1 increased 8-fold (from 130 to 1,100 pg/mL) from gestational weeks 5-12 ( Figure 3 ), followed by a leveling off. In SGA pregnancies, the soluble Flt-1 increase in early pregnancy was much weaker than in control pregnancies, but from 16 weeks of gestation, soluble Flt-1 levels in SGA pregnancies were roughly the same as in controls.
The cross-sectional analysis from the first sampling shows that low levels of soluble Flt-1 were associated with higher risk of SGA delivery. At the second sampling, however, the higher risk of SGA delivery was associated with high soluble Flt-1 levels (Figure 4) . In the longitudinal analysis of soluble Flt-1 changes (Table 3) , women with low soluble Flt-1 (lowest third) at the first sampling and high soluble Flt-1 (highest third) at the second sampling were at 6 times higher risk of SGA delivery (OR ¼ 6.2, 95% CI: 2.4, 16.1), compared with women with soluble Flt-1 in the middle third at both samplings.
Soluble endoglin
In control pregnancies, soluble endoglin levels remained stable at approximately 6 ng/mL until about 26 weeks of pregnancy, followed by a rapid increase in soluble endoglin levels. In comparison, soluble endoglin levels in SGA pregnancies were similar to those in controls until around 16 weeks, after which soluble endoglin levels were consistently higher in SGA compared with control pregnancies ( Figure  5) .
The cross-sectional analysis from the first sampling period showed no clear association of soluble endoglin with risk of SGA delivery but, in the second period, high soluble endoglin was strongly associated with increased risk (Figure 6 ).
The longitudinal analysis (Table 4) shows that women in the highest third of soluble endoglin in the second sampling period were at approximately 3.5 times higher risk of SGA delivery than were women with lower soluble endoglin, and that the risk increase was independent of the soluble endoglin level in the first trimester.
Combined effects of PlGF, soluble Flt-1, and soluble endoglin
In women with a large increase (from lowest to highest third) in soluble Flt-1 relative to PlGF from the first to the second sampling, the risk of SGA delivery was highly increased (OR ¼ 7.8, 95% CI: 2.6, 23.5), compared with women in the middle third of the soluble Flt-1/PlGF ratio at both samplings (Table 5) .
In a separate analysis, we combined the soluble Flt-1/ PlGF ratio and soluble endoglin at the second sampling and assessed the effects on SGA risk, stratified by soluble Flt-1 level at the first sampling ( Table 6 ). The results showed that women with low soluble Flt-1 at the first sampling, combined with a high soluble Flt-1/PlGF ratio and high soluble endoglin at the second sampling, were at extremely high risk of SGA delivery (OR ¼ 24.3, 95% CI: 7.9, 74.3), compared with women with high soluble Flt-1 at the first sampling and a low soluble Flt-1/PlGF ratio and low soluble endoglin at the second sampling.
DISCUSSION
In this nested case-control study of women without preeclampsia within a large cohort of pregnant women, angiogenic factors in maternal circulation measured during in the first 30 weeks of pregnancy were strongly associated with delivery of an SGA infant. In particular, an angiogenic profile characterized by low soluble Flt-1 in the first trimester, followed by a strong increase in soluble Flt-1 relative to PlGF, combined with high levels of soluble endoglin in the second trimester, was associated with a very high SGA risk.
We restricted SGA to infants with a birth weight lower than the 2.5th percentile in an attempt to increase the proportion of cases with true and severe growth restriction. Figure 5 . Geometric mean levels of soluble endoglin by week of gestation, in small-for-gestational-age (SGA) and control pregnancies, adjusted for maternal age and parity, in a case-control study among pregnancies in Norway between 1992 and 1994. However, causes of SGA are heterogeneous, and some infants are naturally small; therefore, we may have underestimated the association of angiogenic factors with true fetal growth restriction. Maternal serum was stored at -20 o C for approximately 10 years before analyses. Storage time could affect serum concentrations, but a possible deterioration in angiogenic factor levels is not likely to differ systematically between SGA and control pregnancies. Changes in angiogenic factors could only be studied in pregnancies where serum was collected at 2 occasions and, therefore, the longitudinal analyses included fewer pregnancies than the cross-sectional analyses from each sampling period. Nonetheless, the longitudinal results yielded strong and precise associations, and the main findings are not likely to be due to chance.
Some prior studies have assessed the effects on fetal growth related to angiogenic factors and found that SGA pregnancies may be characterized by low maternal PlGF (8, 9, (15) (16) (17) (18) (19) (20) (21) (22) and high soluble endoglin levels (5, 6, 9, 12). For soluble Flt-1, results related to intrauterine growth restriction are not consistent. The results of some studies suggest that high soluble Flt-1 in the second or third trimester is associated with high risk (7, 12, 15, 16, (21) (22) (23) , but other studies have shown no association (5, 9, 18, 28) . In a study of angiogenic factors in the first trimester, low soluble Flt-1 levels were associated with increased risk of fetal growth restriction (10); however, other studies of soluble Flt-1 levels in the first trimester have shown no association with SGA risk (5, 20) . Few studies have longitudinal measurements of angiogenic factors during pregnancy and, therefore, the effects on fetal growth of angiogenic activity throughout pregnancy are not resolved. In particular, the effects related to angiogenic factor levels measured before 12 weeks of gestation, combined with later angiogenic activity, have not been properly studied.
Both fetal growth restriction and preeclampsia may be manifestations of placental insufficiency, and studies of preeclampsia could therefore provide additional insight into the placental regulation of angiogenesis. Several studies indicate that low maternal PlGF combined with high soluble Flt-1, or high levels of soluble endoglin in the second trimester, is associated with increased risk of preeclampsia (6). In Figure 6 . Odds ratios of delivery of a small-for-gestational-age (SGA) infant, by levels of soluble endoglin in the first (left) and second (right) sampling period, adjusted for maternal age, parity, and gestational week of sampling, in a case-control study among pregnancies in Norway between 1992 and 1994. The odds ratios are calculated at 5, 10, 20, 30, 40, 50, 60, 70, 80, 90 , and 95 percentiles of soluble endoglin, by using the 50th percentile as the reference. CI, confidence interval; OR, odds ratio. particular, a combination of low soluble Flt-1 in the first trimester but high soluble Flt-1 later in pregnancy has been associated with increased risk of preterm preeclampsia (5, 26) , a condition that is often accompanied by a small infant. In pregnancy, the placenta is an important source of angiogenic factors that promote and regulate development of vessels that secure oxygen and nutritional supply to the fetus. Flt-1 is a receptor of vascular endothelial growth factor (VEGF); soluble Flt-1 is the soluble form of this receptor and binds to VEGF and PlGF (13, 29, 30) . Similarly, soluble endoglin is the soluble form of endoglin, which is a coreceptor of transforming growth factor b (6, 31). VEGFs and their receptors, including soluble Flt-1, are highly expressed in the first trimester (29, 32, 33) , and it seems plausible that low soluble Flt-1 in the first trimester could reflect low angiogenic activity and thereby impaired placental development.
One consequence of the placental impairment may be fetoplacental hypoxia, which is a threat to the survival of the fetus. A strong subsequent angiogenic activity may be interpreted as a response to hypoxia, and high levels of soluble Flt-1 and soluble endoglin may be markers of this activity (7, 11, 13, 14) . The angiogenic profile associated with extremely high risk of SGA in our study was characterized by low levels of soluble Flt-1 in early pregnancy followed by high levels of soluble Flt-1 relative to PlGF and high soluble endoglin later in pregnancy. This suggests that the angiogenic activity represented by VEGFs and transforming growth factor b could provide a coordinated response to fetoplacental hypoxia.
In addition to being markers or correlates of proangiogenic activity, soluble Flt-1 and soluble endoglin exert antiangiogenic effects. In the mother, there is strong evidence that high soluble Flt-1 and high soluble endoglin levels lead to endothelial dysfunction and mediate the maternal hypertension and proteinuria that are characteristic for preeclampsia (6, 13, (29) (30) (31) . In the fetus, it is possible that high soluble Flt-1 (22, 34) and high soluble endoglin levels could cause vascular effects that in the long term may be important for the well-established association of low birth weight with long-term risk of vascular disease in adulthood (2) . Possibly, both of these effects could be adaptive responses to impaired placental function (35) . Angiogenic factors may display similar patterns in relation to both preeclampsia and SGA but, nonetheless, the absolute angiogenic factor levels may differ. From some studies that included both SGA and preeclamptic pregnancies, it may be suggested that soluble Flt-1 levels are higher in preeclamptic women, compared with normotensive women with SGA delivery (9, 18) . Therefore, it is possible that very high maternal soluble Flt-1 levels are required for preeclampsia to develop.
In summary, an angiogenic profile that is characterized by low maternal soluble Flt-1 levels in early pregnancy, followed by a strong subsequent response indicated by high soluble Flt-1 and soluble endoglin levels, is associated with high risk of severe growth restriction in the offspring.
